New drug targets genetic weakness in Hard-to-Treat blood cancers
NCT ID NCT02719574
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is to see if it is safe and effective at shrinking or eliminating the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FT-2102 (olutasidenib)
What this could lead to
If successful, this could provide a new targeted treatment option for people with IDH1-mutated AML or MDS, potentially improving remission rates.
What could go wrong
This is an early-phase trial, so the drug may not work as hoped or could cause serious side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU S. Luigi Gonzaga - Orbassano
Orbassano, Turin, Italy
-
Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital Nord
Marseille, 13005, France
-
Box Hill Hospital, Monash University and Eastern Health Clinical School
Box Hill, 3128, Australia
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire (CHU) Bordeaux - Hospitaux du Haut Leveque
Pessac, 33604, France
-
Centre Hospitalier Universitaire Nantes
Nantes, 44093, France
-
Centre Hospitalier Universitaire de Nancy - Hopital Brabois
Vandœuvre-lès-Nancy, 54511, France
-
Churchill Hospital
Oxford, United Kingdom
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Cornell University Weill Medical College
New York, New York, 10065, United States
-
Dipartimento di Oncologia Medica - IRST IRCC
Meldola, Italy
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hopitaux Universitaires Est Parisien Hopital Saint-Antoine
Paris, 75012, France
-
Hospital Clinic de Barcelona
Barcelona, 8036, Spain
-
Hospital Clínico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital La Fe
Valencia, 46026, Spain
-
Hospital Rimini Hematology, Department of Oncology and Hematoloy
Rimini, Italy
-
Hospital Universitario 12 De Octubre
Madrid, 28041, Spain
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
Hôpital Saint-Louis
Paris, 75010, France
-
Institut Català d'Oncologia-Hospital Duran i Reynals
Barcelona, 8908, Spain
-
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, 31059, France
-
Institut de Cancérologie Gustave Roussy
Villejuif, 94805, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Landeszentrum fuer Zell- und Gentherapie
Halle, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
New York Medical College
Hawthorne, New York, 10532, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Oregon Health & Science University
Portland, Oregon, 97229, United States
-
Ospedale Mazzoni - UOC Ematologia Ascoli Piceno
Ascoli Piceno, Italy
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Gumi, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris
Bobigny, 93000, France
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
Southampton General Hospital
Southampton, United Kingdom
-
St. George's University Hospital
London, United Kingdom
-
Staedtisches Klinikum Braunschweig gGmbH
Braunschweig, Germany
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
U.O. Ematologia Ravenna
Ravenna, Italy
-
UC Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
UCLA Medical Center
Los Angeles, California, 90024, United States
-
Universita di Bologna
Bologna, Italy
-
Universitaetsklinikum Giessen und Marburg GmbH - Klinik fuer Innere Medizin
Giessen, Germany
-
University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
University Hospital of Rennes
Rennes, 35033, France
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Università degli Studi di Parma
Parma, Italy
-
Universitätsklinikum Münster Medizinische Klinik A, Hämatologie, Hämostaseologi
Münster, Germany
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Victoria Cancer Care Center
Parkville, Victoria, 3000, Australia
-
Yale University
New Haven, Connecticut, 06510, United States